Tom Baker Cancer Centre
Calgary, Alberta, T2N 4N2, Canada
NCT Number: NCT00125684
Patients will participate in two arms of the trial, one in which morphine will be administered transdermally, and, after a 3 day wash out period, one in which morphine will be administered subcutaneously.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1
Calgary, Alberta, T2N 4N2, Canada
Patients will participate in two arms of the trial, one in which morphine will be administered transdermally, and, after a 3 day wash out period, one in which morphine will be administered subcutaneously. Blood draws will be done after both dosing methods in order to compare blood levels of morphine by the different routes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Alberta Health services
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03146806
Cancer, Cancer Pain
Atlanta, Georgia, United States
View Trial DetailsNCT03176199
Cancer, Cancer Pain
Chang-hua, Taiwan
View Trial DetailsNCT03176121
Cancer, Cancer Pain
Chang-hua, Taiwan
View Trial DetailsNCT00125294
Breakthrough Pain, Cancer
View Trial Details